<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556345</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C008</org_study_id>
    <nct_id>NCT03556345</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2</brief_title>
  <official_title>A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or
      metastatic gastric patients with the overexpression of HER2.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as Assessed by investigator</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Tumor response was assessed by investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS was defined as the time from the first study treatment to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>HER2 Overexpressing Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <description>2.5 mg/kg IV every 2 weeks</description>
    <arm_group_label>RC48-ADC</arm_group_label>
    <other_name>Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary agreement to provide written informed consent.

          -  Male or female, Age ≥ 18 years and ≤ 80 years.

          -  Predicted survival ≥ 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          -  All female subjects will be considered to be of child-bearing potential unless they
             are postmenopausal, or have been sterilized surgically.Female subjects of
             child-bearing potential must agree to use two forms of highly effective contraception.
             Male subjects and their female partner who are of child-bearing potential must agree
             to use two forms of highly effective contraception.

          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions
             specified in this protocol.

          -  Adequate organ function.

          -  Have had progression or intolerance following receipt of at least two systemic
             chemotherapy for advanced or metastatic disease.

          -  HER2 overexpression defined as HER2 IHC 2+ or 3+.

          -  Measurable disease according to RECIST 1.1.

        Exclusion Criteria:

          -  Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE
             Conjugate For Injection.

          -  History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to
             trial treatment.

          -  History of major surgery within 4 weeks of planned start of trial treatment.

          -  Has received a live virus vaccine within 4 weeks of planned start of trial treatment.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  History of other malignancy within the previous 5 years, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with
             a similar curative outcome as those mentioned above.

          -  Assessed by the investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RC48-ADC</keyword>
  <keyword>HER2 overexpression</keyword>
  <keyword>Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

